Uniting Large Pharma, Innovative Biotech & Leading Academics Dedicated to Accelerating the Discovery of Next-Generation GPCR-Targeted Therapeutics

GPCRs-targeted drug discovery continues to gain exponential momentum, with advances in screening tools, characterization of dynamic confirmations and basic GPCR biology, including orphan receptors.  Coupled with numerous strategic collaboration and investment, the GPCR field is fuelling for the clinical progression of next-generation small molecules and biologics across a spectrum of indications and previously undrugged GPCR targets.

Owing to this, the Annual GPCRs-Targeted Drug Discovery Summit returns for its 3rd year as the world’s only and most comprehensive industry dedicated GPCR forum. Bringing two brand new specialized tracks of content (Target ID & Validation and Hit ID & Optimization), don’t miss out on your ultimate chance to unite with 100+ GPCR experts devoted to accelerating the discovery of new, transformative small molecules and biologics.

What's New for 2024?

https://gpcrs-drugdiscovery.com/wp-content/uploads/sites/646/2021/10/cropped-HW211013-GPCRs-Targeted-Drug-Discovery-Summit-logo-FINAL-WO.png

Two brand new tracks of specialized content (Target ID & Validation and Hit ID & Optimization) covering the latest advances in screening, biochemical optimization, target validation and progressing the wave of next-generation small molecules and biologics into pre-clinical and clinical settings.

https://gpcrs-drugdiscovery.com/wp-content/uploads/sites/646/2021/10/cropped-HW211013-GPCRs-Targeted-Drug-Discovery-Summit-logo-FINAL-WO.png

A new cohort of expert speakers and companies presenting from the likes of Pfizer, Sosei Heptares, Superluminal Medicines & AstraZeneca.

https://gpcrs-drugdiscovery.com/wp-content/uploads/sites/646/2021/10/cropped-HW211013-GPCRs-Targeted-Drug-Discovery-Summit-logo-FINAL-WO.png

An expert-led pre-conference focus day harnessing advanced computing across the GPCR-targeted drug pipeline including the latest developments in virtual screening, the best practices in structure-based drug design and mapping novel disease targets to ultimately streamline hit-to-lead generation.

Don’t miss out on your ultimate chance to unite with 100+ GPCR experts devoted to accelerating the discovery of new, transformative small molecules and biologics.

2024 Expert Speakers Include

A Snapshot of 2023 Attendees

2023 speaker

2024 Partners

wuxi-biortus-biosciences
logo_leadXpro_screen_discoverygreen_rgb[32]
logotype_EF_01[95]
Nanoimaging-e1676027511620 (1)[11]
1. LCC Primary Logo Green Orange 1 (1)